Rogers Corp (ROG)

127.90
0.40 0.31
NYSE : Technology
Prev Close 127.50
Open 127.03
Day Low/High 127.03 / 127.99
52 Wk Low/High 51.98 / 128.00
Volume 15.33K
Avg Volume 118.90K
Exchange NYSE
Shares Outstanding 18.22M
Market Cap 2.30B
EPS 2.70
P/E Ratio 30.48
Div & Yield N.A. (N.A)

Latest News

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Pharma giant aims to develop cancer drug delivery technology. Halozyme shares are up more than 16% in pre-market trading.

Genentech Provides Update On First Lampalizumab Phase III Study For Geographic Atrophy, An Advanced Form Of Age-Related Macular Degeneration

Genentech Provides Update On First Lampalizumab Phase III Study For Geographic Atrophy, An Advanced Form Of Age-Related Macular Degeneration

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary endpoint has not been met in Spectri, the first of two Phase III studies evaluating the safety and efficacy of...

Rogers To Participate In Drexel Hamilton TMT Conference

Rogers To Participate In Drexel Hamilton TMT Conference

Rogers Corporation (NYSE:ROG) today announced Senior Vice President and CTO, Bob Daigle, will be presenting at the Drexel Hamilton Telecom, Media and Technology Conference in New York on Wednesday September 6 at...

FDA Approves Genentech's Actemra (Tocilizumab) For The Treatment Of CAR T Cell-Induced Cytokine Release Syndrome

FDA Approves Genentech's Actemra (Tocilizumab) For The Treatment Of CAR T Cell-Induced Cytokine Release Syndrome

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Grants Priority Review For Genentech's Gazyva In Previously Untreated Follicular Lymphoma

FDA Grants Priority Review For Genentech's Gazyva In Previously Untreated Follicular Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Grants Priority Review To Genentech's Emicizumab For Hemophilia A With Inhibitors

FDA Grants Priority Review To Genentech's Emicizumab For Hemophilia A With Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Save The Date: Rogers To Host Investor Day August 17

Save The Date: Rogers To Host Investor Day August 17

Rogers Corporation (NYSE:ROG) Save the Date. Rogers Corporation plans to host an investor day the morning of August 17 at the New York Stock Exchange.

FDA Grants Priority Review And Breakthrough Therapy Designation For Zelboraf (vemurafenib) In Erdheim-Chester Disease With BRAF V600 Mutation

FDA Grants Priority Review And Breakthrough Therapy Designation For Zelboraf (vemurafenib) In Erdheim-Chester Disease With BRAF V600 Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Rogers Corporation Appoints Jeff Owens To Its Board Of Directors

Rogers Corporation Appoints Jeff Owens To Its Board Of Directors

Rogers Corporation (NYSE:ROG) today announced that its Board of Directors appointed Jeffrey J.

FDA Grants Genentech's Alecensa Priority Review For Initial Treatment Of People With ALK-Positive Lung Cancer

FDA Grants Genentech's Alecensa Priority Review For Initial Treatment Of People With ALK-Positive Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Rogers Corporation Reports Second Quarter 2017 Results

Rogers Corporation Reports Second Quarter 2017 Results

Rogers Corporation (NYSE:ROG) today announced financial results for the 2017 second quarter.

Roche To Showcase Power Of Connected Lab At AACC 2017 Clinical Lab Expo

Roche To Showcase Power Of Connected Lab At AACC 2017 Clinical Lab Expo

- Concept amplifies impact of diagnostics to help improve patient management

Positive Phase III Results Of Genentech's Actemra (Tocilizumab) For The Treatment Of Giant Cell Arteritis Published In New England Journal Of Medicine

Positive Phase III Results Of Genentech's Actemra (Tocilizumab) For The Treatment Of Giant Cell Arteritis Published In New England Journal Of Medicine

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that data from the Phase III GiACTA study, which evaluated Actemra ® (tocilizumab) in adult patients with GCA, were published in the...

Accenture To Transform Diabetic Patient Care Using Data-driven Analytics Platform

Accenture To Transform Diabetic Patient Care Using Data-driven Analytics Platform

Accenture (NYSE: ACN) is collaborating with Roche (SIX: RO, ROG; OTCQX: RHHBY) to improve how diabetes care is managed and delivered through the development of a data-driven core analytics platform for Roche's digital...

Roche Launches The AVENIO Millisect System For Precise And Efficient Dissection Of Tissue Biopsies

Roche Launches The AVENIO Millisect System For Precise And Efficient Dissection Of Tissue Biopsies

- AVENIO Millisect System utilizes an automated, digitally assisted process to reliably and efficiently isolate clinically relevant cells for diagnostic testing

Rogers Schedules Second Quarter 2017 Earnings Call For August 1

Rogers Schedules Second Quarter 2017 Earnings Call For August 1

Rogers Corporation (NYSE:ROG) plans to announce second quarter 2017 results on July 31 after market close, which will be followed by a conference call on August 1 at 9am ET.

5 New Breast Cancer Treatments That Are Helping to Save Lives

5 New Breast Cancer Treatments That Are Helping to Save Lives

In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.

Rogers To Participate In CJS Summer Conference

Rogers To Participate In CJS Summer Conference

Rogers Corporation (NYSE:ROG) today announced Senior Vice President and CTO, Bob Daigle, will be presenting at the CJS Summer Conference in New York on Tuesday, July 11 at 8:00 am EDT.

Positive Phase III Results For Genentech's Emicizumab In Hemophilia A Published In The New England Journal Of Medicine

Positive Phase III Results For Genentech's Emicizumab In Hemophilia A Published In The New England Journal Of Medicine

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that data from HAVEN 1, a Phase III study evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) in adults and...

Celgene Enters PD1 Market with BeiGene Deal

Celgene Enters PD1 Market with BeiGene Deal

Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.

Roche Expands Harmony® Prenatal Test To Include 22q11.2 Deletion Testing

-- New test option will be available globally mid-2017 in the Harmony CE-IVD kit and through the test send-out service from Ariosa Diagnostics Inc.

Genentech's Emicizumab Showed Positive Results In Phase III Studies (HAVEN 1 And HAVEN 2) In Hemophilia A With Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive data from the primary analysis of the Phase III HAVEN 1 study in adults and adolescents and interim analysis of the Phase III...

Roche Receives FDA Approval For Fourth-generation HIV Combination Antigen-antibody Assay --allowing Detection Of Infection With High Sensitivity And Specificity

Elecsys® HIV combi PT assay demonstrates commitment to improving efficiency by aiding labs in consolidating testing with other routine immunoassays

New Data At EAN Show Genentech's Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures Of Disease Progression In Relapsing And Primary Progressive Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new post-hoc analyses from the OCREVUS TM (ocrelizumab) Phase III clinical trial program in people with relapsing and primary...

FDA Approves RITUXAN HYCELA (Rituximab And Hyaluronidase Human) For Subcutaneous Injection In Certain Blood Cancers

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Save The Date: Rogers To Host Investor Day August 17

Rogers Corporation (NYSE:ROG) Save the Date. Rogers Corporation plans to host an investor day the morning of August 17 at the New York Stock Exchange.

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat

TheStreet Quant Rating: A (Buy)